Published in J Cutan Pathol on August 23, 2011
Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma. Cancer Med (2016) 0.80
Multiple Merkel cell carcinomas: Late metastasis or multiple primary tumors? A molecular study. JAAD Case Rep (2017) 0.75
Distinct sets of genetic alterations in melanoma. N Engl J Med (2005) 17.26
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature (2008) 8.42
Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol (2006) 7.76
Mutations in GNA11 in uveal melanoma. N Engl J Med (2010) 7.52
In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res (2006) 4.29
The Genetic Evolution of Melanoma from Precursor Lesions. N Engl J Med (2015) 4.24
Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet (2011) 3.91
Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst (2003) 3.65
KIT as a therapeutic target in metastatic melanoma. JAMA (2011) 3.49
Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci U S A (2003) 2.87
MC1R germline variants confer risk for BRAF-mutant melanoma. Science (2006) 2.84
Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol (2010) 2.83
Molecular subsets in the gene expression signatures of scleroderma skin. PLoS One (2008) 2.66
Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat Cell Biol (2006) 2.58
Improving melanoma classification by integrating genetic and morphologic features. PLoS Med (2008) 2.52
Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell (2013) 2.43
Temporal dissection of tumorigenesis in primary cancers. Cancer Discov (2011) 2.40
AFX: what we now know. J Cutan Pathol (2011) 2.36
Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol (2008) 2.35
Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol (2010) 2.30
Frequent mutations in the MITF pathway in melanoma. Pigment Cell Melanoma Res (2009) 2.27
Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. J Invest Dermatol (2006) 2.04
Removing the unknown from the carcinoma of unknown primary. J Clin Oncol (2012) 1.99
Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res (2008) 1.98
Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev (2007) 1.98
Memory regulatory T cells reside in human skin. J Clin Invest (2014) 1.95
Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci U S A (2013) 1.88
Cocaine-associated retiform purpura and neutropenia: is levamisole the culprit? J Am Acad Dermatol (2010) 1.87
Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma. Am J Surg Pathol (2009) 1.87
Ambiguous melanocytic tumors with loss of 3p21. Am J Surg Pathol (2014) 1.83
The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res (2011) 1.81
Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res (2002) 1.78
Frequent p16-independent inactivation of p14ARF in human melanoma. J Natl Cancer Inst (2008) 1.78
Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol (2011) 1.78
MC1R variants increase risk of melanomas harboring BRAF mutations. J Invest Dermatol (2008) 1.72
A full-coverage, high-resolution human chromosome 22 genomic microarray for clinical and research applications. Hum Mol Genet (2002) 1.69
Perineural spread of malignant melanoma of the head and neck: clinical and imaging features. AJNR Am J Neuroradiol (2004) 1.65
Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res (2005) 1.65
A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression. Am J Surg Pathol (2012) 1.57
Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy. Pigment Cell Melanoma Res (2013) 1.56
Ducking stray "magic bullets": a Melan-A alert. Am J Dermatopathol (2003) 1.55
Genetic and morphologic features for melanoma classification. Pigment Cell Melanoma Res (2010) 1.47
BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res (2011) 1.47
Batman and adnexal tumors. J Cutan Pathol (2010) 1.46
Metastatic melanoma in association with a giant congenital melanocytic nevus in an adult: controversial CGH findings. Am J Dermatopathol (2015) 1.45
The amount counts: distinguishing neutrophil-mediated and lymphocyte-mediated cicatricial alopecia by compound follicles. J Cutan Pathol (2011) 1.43
Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity. Arch Dermatol (2010) 1.43
Mutation-driven drug development in melanoma. Curr Opin Oncol (2010) 1.43
Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem (2004) 1.43
The presence of polyomavirus in non-melanoma skin cancer in organ transplant recipients is rare. J Invest Dermatol (2008) 1.43
Distinguishing neurofibroma from desmoplastic melanoma: the value of the CD34 fingerprint. J Cutan Pathol (2011) 1.42
A spindled cell CD34+ dermal proliferation. Am J Dermatopathol (2002) 1.40
Cut it out. J Cutan Pathol (2010) 1.39
Neurofibroma-like spindle cell melanoma: CD34 fingerprint and CGH for diagnosis. Am J Dermatopathol (2012) 1.38
Primary linear closure for large defects of the nasal supratip. Dermatol Surg (2008) 1.38
Second-intention healing of nasal alar defects. Dermatol Surg (2011) 1.37
Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control (2007) 1.32
Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. Proc Natl Acad Sci U S A (2002) 1.30
Selection of tumorigenic melanoma cells using ALDH. J Invest Dermatol (2010) 1.27
Sunitinib therapy for melanoma patients with KIT mutations. Clin Cancer Res (2012) 1.23
Sporadic naturally occurring melanoma in dogs as a preclinical model for human melanoma. Pigment Cell Melanoma Res (2013) 1.20
PI3-kinase subunits are infrequent somatic targets in melanoma. J Invest Dermatol (2006) 1.19
Mycosis fungoides: the great imitator. J Am Acad Dermatol (2002) 1.17
Distinguishing melanocytic nevi from melanoma by DNA copy number changes: comparative genomic hybridization as a research and diagnostic tool. Dermatol Ther (2006) 1.16
Baldy. J Cutan Pathol (2010) 1.16
Tumor fistulization associated with targeted therapy: computed tomographic findings and clinical consequences. J Comput Assist Tomogr (2011) 1.15
Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma. Mol Cancer Res (2009) 1.14
Correction and clarification regarding AFX and pleomorphic dermal sarcoma. J Cutan Pathol (2012) 1.13
The role of a positron- and high-energy gamma photon probe in intraoperative localization of recurrent melanoma. Clin Nucl Med (2005) 1.13
Germline variation controls the architecture of somatic alterations in tumors. PLoS Genet (2010) 1.11
Activated stat-3 in melanoma. Cancer Control (2008) 1.11
In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. Mol Cancer Ther (2005) 1.11
Perifollicular xanthomatosis as the hallmark of axillary Fox-Fordyce disease: an evaluation of histopathologic features of 7 cases. Arch Dermatol (2008) 1.11
Molecular analysis of a case of nevus of ota showing progressive evolution to melanoma with intermediate stages resembling cellular blue nevus. Am J Dermatopathol (2010) 1.08
A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: creation and rationale for inclusion of tumor (T) characteristics. J Am Acad Dermatol (2011) 1.06
Clonal BRAF mutations in melanocytic nevi and initiating role of BRAF in melanocytic neoplasia. J Natl Cancer Inst (2013) 1.06
Loss of the p53/p63 regulated desmosomal protein Perp promotes tumorigenesis. PLoS Genet (2010) 1.04
The stiff skin syndrome: case series, differential diagnosis of the stiff skin phenotype, and review of the literature. Arch Dermatol (2008) 1.03
Distribution and significance of occult intraepidermal tumor cells surrounding primary melanoma. J Invest Dermatol (2008) 1.03
Presentation of extranodal natural killer T-cell lymphoma, nasal type, with poorly circumscribed erythematous patches. J Clin Oncol (2009) 1.03
Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma. Melanoma Res (2009) 1.02
Treatment of cutaneous melanoma: current approaches and future prospects. Cancer Manag Res (2010) 1.01
GNAQ and GNA11 mutations in melanocytomas of the central nervous system. Acta Neuropathol (2012) 1.00
The magic tool. J Cutan Pathol (2010) 1.00
Brother (and sister), can you spare the S100? J Cutan Pathol (2010) 0.99
Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell Melanoma Res (2014) 0.99
Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma. J Clin Oncol (2013) 0.98
KIT as a therapeutic target in melanoma. J Invest Dermatol (2010) 0.97
Uncommon manifestations of common malignancies: case 3. Malignant melanoma arising from a spinal nerve root. J Clin Oncol (2004) 0.97
Mechanisms of cell-cycle arrest in Spitz nevi with constitutive activation of the MAP-kinase pathway. Am J Pathol (2004) 0.97
Intraoperative frozen section analysis of sentinel lymph nodes in breast cancer patients: a meta-analysis and single-institution experience. Cancer (2010) 0.95
Two pediatric cases of nonbullous histiocytoid neutrophilic dermatitis presenting as a cutaneous manifestation of lupus erythematosus. Arch Dermatol (2008) 0.94
Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta. Clin Cancer Res (2005) 0.94
Xanthogranulomas associated with hematologic malignancy in adulthood. J Am Acad Dermatol (2008) 0.93
Persistent (recurrent) Spitz nevi: a histopathologic, immunohistochemical, and molecular pathologic study of 22 cases. Am J Surg Pathol (2002) 0.93
Hyperthermic injury to adipocyte cells by selective heating of subcutaneous fat with a novel radiofrequency device: feasibility studies. Lasers Surg Med (2010) 0.92
Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database. Cancer Control (2006) 0.92